December 20, 2019Open Access

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Palandri et al. (Fri,) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554bb https://doi.org/https://doi.org/10.1002/cncr.32664

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib2018 · 14 citations
2The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention2015 · 1,581 citations
3DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status2010 · 1,032 citations
4Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs2012 · 458 citations
5Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis2010 · 186 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo